Centaurus Financial Inc. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,413 shares of the medical research company's stock, valued at approximately $1,236,000.
Several other hedge funds have also added to or reduced their stakes in the stock. Adell Harriman & Carpenter Inc. raised its stake in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen during the fourth quarter valued at $22,441,000. Sigma Planning Corp boosted its position in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock valued at $5,889,000 after buying an additional 3,488 shares during the last quarter. Integrated Advisors Network LLC increased its holdings in Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after buying an additional 6,356 shares in the last quarter. Finally, National Pension Service increased its holdings in Amgen by 4.7% in the 4th quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock worth $405,717,000 after buying an additional 55,489 shares in the last quarter. 76.50% of the stock is owned by institutional investors.
Insider Buying and Selling at Amgen
In related news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 over the last quarter. 0.85% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. Truist Financial upped their target price on shares of Amgen from $340.00 to $362.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 13th. TD Cowen lifted their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Mizuho increased their price target on Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a report on Tuesday, August 18th. Finally, Scotiabank raised their price target on Amgen from $385.00 to $450.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $380.43.
Read Our Latest Analysis on Amgen
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Tezspire posted strong Phase 3 results in eosinophilic esophagitis (EoE). The drug met both co-primary and all key secondary endpoints, producing statistically significant and clinically meaningful improvements in tissue inflammation and difficulty swallowing. Benefits were sustained through 52 weeks, supporting a potential third approved indication beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 results
- Positive Sentiment: The EoE opportunity could materially expand Tezspire’s commercial potential. Analysts and industry commentators view EoE as a possible blockbuster market, potentially allowing Amgen and partner AstraZeneca to compete more directly with established biologics such as Dupixent. Regulatory filing and approval remain necessary before the opportunity can translate into revenue. Tezspire EoE market opportunity
- Neutral Sentiment: Amgen began a Phase 1 study of AMG 691 aimed at a potentially important Asian market. The trial could add a long-term growth asset, but it is at an early stage and provides limited near-term earnings visibility. AMG 691 Phase 1 trial
- Negative Sentiment: Amgen ended its Crohn’s disease research collaboration with TScan Therapeutics. The decision removes an exclusive effort to identify and develop T-cell targets in inflammatory bowel disease, narrowing one element of Amgen’s early pipeline and highlighting uncertainty around its partnership strategy. Amgen ends Crohn’s disease partnership
Amgen Stock Performance
Shares of NASDAQ AMGN opened at $436.99 on Friday. The firm has a 50 day moving average of $386.75 and a 200 day moving average of $364.23. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $236.25 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 3.18 and a beta of 0.41. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $447.03.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. During the same period in the prior year, the company earned $6.02 earnings per share. The firm's revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.92 earnings per share for the current year.
Amgen Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's dividend payout ratio (DPR) is currently 62.65%.
Amgen Company Profile
(
Free Report)
Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
